CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese

被引:25
作者
Chern, HD
Ueng, TH
Fu, YP
Cheng, CW
机构
[1] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan
[2] Natl Taiwan Univ, Coll Med, Grad Inst Clin Pharm, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, Taipei, Taiwan
[4] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan
关键词
warfarin; CYP2C9; DNA sequencing; SNP; PCR-PFLP;
D O I
10.1016/j.cca.2005.11.026
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Warfarin prevents thromboembolism in patients with prosthetic heart valvular replacement. Cytochrome P4502C9 (CYP2C9) is polymorphic in human and is principally responsible for the metabolism of warfarin. However, known CYP2C9 polymorphisms cannot entirely account for the low dose requirement of warfarin in Chinese-Taiwanese receiving mitral valve replacement. We screened a new polymorphism of CYP2C9 and investigated its role in warfarin sensitivity. Methods: We examined warfarin dose requirements in 239 Chinese-Taiwanese patients who had attended a cardiac surgery clinic in National Taiwan University Hospital. DNA samples were obtained from 106 Chinese-Taiwanese (37 patients and 69 unrelated healthy controls), and healthy control subjects of Caucasians (n=28) and African-Americans (n=28). Four out. of those 37 patients were poor metabolizers of warfarin, and their DNA were subjected to sequencing analysis. Moreover, CYP2C9 genotyping analyses were performed using PCR-RFLP analysis. The chi(2) test and Fisher's exact test were used to compare the differences of the allelic frequency and genotype. The association between warfarin dose requirement and genetic polymorphism of CYP2C9 was also analysed. Results: The mean daily warfarin dose was 3.11 +/- 1.62 mg for the maintenance of the international normalized ratio of 2 to 3 in 239 patients. A single nucleotide substitution from G to C was found in this study. This SNP, G_(65)/C, is in intron 3, 65 base pairs upstream of exon 4. The allelic frequencies of C-65 in healthy controls were 0.125, 0.058 and similar to 0 with respect to African-American, Chinese-Taiwanese and Caucasian, implying inter-ethnic variations of the C-65 allele. In addition, patients who were carrier of either the heterozygous or homozygous C-65 variant received half of the usual warfarin dose. Conclusion: The novel intronic G(-65)/C mutation appears to be inter-racially different in allelic frequency, and that the anticoagulation was affected in response to warfarin sensitivity in Chinese-Taiwanese patients receiving mitral valve replacement. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 34 条
  • [1] Chenhsu RY, 2000, ANN PHARMACOTHER, V34, P1395
  • [2] Daly Ann K, 2003, Semin Vasc Med, V3, P231
  • [3] The influence of ethnicity on warfarin dosage requirement
    Dang, MTN
    Hambleton, J
    Kayser, SR
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (06) : 1008 - 1012
  • [4] FINN SD, 1996, ANN INTERN MED, V124, P970
  • [5] FONG PC, 1993, J HONG KONG COLL CAR, V1, P13
  • [6] Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
    Furuya, H
    FernandezSalguero, P
    Gregory, W
    Taber, H
    Steward, A
    Gonzalez, FJ
    Idle, JR
    [J]. PHARMACOGENETICS, 1995, 5 (06): : 389 - 392
  • [7] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
    Haining, RL
    Hunter, AP
    Veronese, ME
    Trager, WF
    Rettie, AE
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) : 447 - 458
  • [8] Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data
    Hillman, Michael A.
    Wilke, Russell A.
    Yale, Steven H.
    Vidaillet, Humberto J.
    Caldwell, Michael D.
    Glurich, Ingrid
    Berg, Richard L.
    Schmelzer, John
    Burmester, James K.
    [J]. CLINICAL MEDICINE & RESEARCH, 2005, 3 (03) : 137 - 145
  • [9] KAMINSKY LS, 1993, MOL PHARMACOL, V43, P234
  • [10] Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
    Kimura, M
    Ieiri, I
    Mamiya, K
    Urae, F
    Higuchi, S
    [J]. THERAPEUTIC DRUG MONITORING, 1998, 20 (03) : 243 - 247